Is it another 'sell-the-news' type of day?Is it another 'sell-the-news' type of day?

Is This Why Ripple’s XRP Dropped to $2 Today?

Another month has started on a similar note as the previous, with the cryptocurrency market bleeding heavily, and nearly $200 billion leaving the space in less than 12 hours.

There seems to be no actual catalysts behind the latest crash, aside from over-leveraged market participants. Nevertheless, some altcoins have been hit worse than others, such as Ripple’s XRP.

While ETH is down by less than 6% daily and BNB has slipped by 5%, XRP has dropped by 7% and dipped to $2 earlier today on most exchanges. As a result, the cross-border token has dipped to a major buy wall serving as a support that managed to hold its free falls in the past.

Interestingly, today’s price decline follows similar movements when spot XRP ETFs were supposed to launch. Recall that the underlying asset plunged after the first such product, released by Canary Capital, hit the US markets in mid-November despite its record-breaking debut day.

Bitwise’s XRP was also impressive on day one, but the token plunged once again, albeit in line with the rest of the cryptocurrency market.

Consequently, many speculate whether today’s expected launch of 21Shares’ spot XRP ETF, which will track the CME CF XRP-Dollar Reference Rate, is another classic sell-the-news event.

The four XRP ETFs already live for trading have attracted over $660 million in total net inflows since the first one launched a few weeks ago. XRPC remains the biggest of the bunch, with more than $340 million in cumulative netflows, followed by Bitwise’s XRP, Franklin’s XRPZ, and Grayscale’s GXRP.

The drop to $2.04 as of press time means XRP trades further in the red on the YTD scale, having entered 2025 at $2.32. This sort of performance is in stark contrast to the year the company behind the token had, which is arguably its best ever.

The post Is This Why Ripple’s XRP Dropped to $2 Today? appeared first on CryptoPotato.

Market Opportunity
XRP Logo
XRP Price(XRP)
$2.0696
$2.0696$2.0696
-1.28%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26